Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies

Pharmaceutical Statistics

Volumn 12, Issue 5, 2013, Pages 300-308

  Whitehead, Anne ^a   Su, Ting Li ^a   Thygesen, Helene ^b   Sperrin, Matthew ^c   Harbron, Chris ^d  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

drug combination; heteroscedasticity; interaction index; Loewe additivity; synergy

Indexed keywords

ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DRUG POTENTIATION; ERROR; MONOTHERAPY; RESPONSE VARIABLE; SIMULATION; STATISTICAL MODEL; STATISTICAL PARAMETERS;

DRUG COMBINATION; HETEROSCEDASTICITY; INTERACTION INDEX; LOEWE ADDITIVITY; SYNERGY;

DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MODELS, BIOLOGICAL;

EID: 84883763323     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1583     Document Type: Article

References (11)

1. Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D,. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. Journal of Pharmacology and Experimental Therapeutics 2011; 338: 732-740.
2. Hill AV,. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curve. Journal of Physiology 1910; 40: 4-7.
3. Loewe S, Muischnek H,. Effect of combinations: mathematical basis of problem. Archives of Experimental Pathology and Pharmacology 1926; 114: 313-326.
4. Hewlett PS,. Measurement of the potencies of drug mixtures. Biometrics 1969; 25: 477-487.
5. Harbron C,. A flexible unified approach to the analysis of the pre-clinical combination studies. Statistics in Medicine 2010; 29: 1746-1756.
6. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22: 27-55.
7. ®. Pharmaceutical Statistics 2008; 7: 272-284.
8. SYNERGY. Software to determine the interaction of two drugs as synergy, additivity or antagonism. Available at: http://biostatistics.mdanderson.org/ SoftwareDownload (accessed 14 March 2012).
9. Lee JJ, Kong M, Ayers GD, Lotan R,. Interaction index and different methods for determining drug interaction in combination therapy. Journal of Biopharmaceutical Statistics 2007; 17: 461-480. (Pubitemid 46699662)
10. Bliss CI,. The toxicity of poisons applied jointly. Annals of Applied Biology 1939; 26: 585-615.
11. Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR,. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Research 1998; 58: 3036-3050. (Pubitemid 28335085)